Published on: 08/29/16
IBD News Today reports on the development of a new class of cannabis derived cannabanoid prodrugs called cannabosides. Cannabosides enable the selective absorption of cannabidiol (CBD) to reach the intestinal tract and reduce the delivery of tetrahydrocannabinol (THC) to the brain.
The prodrug is developed to treat neurological and inflammatory disorders including inflammatory bowel disease (IBD). The medication is metabolized into a pharmacologically active drug to improve bioavailability in the case of poorly absorbed compounds. It may also be used to selectively target specific organs or tissue cells such as the brain or gut.
Medical research has made impressive progress towards CBD from cannabis being classified as an approved treatment for Crohn’s Disease in recent years.
The long-standing aim of medical researchers has been the provision of the benefits of cannabinoids in a more targeted way. This goal could be achieved by cannabosides, which aim to deliver this benefit. The specific therapeutic area which will benefit is gastroenterology.
An estimated 500,000 Americans have Crohn’s disease, an inflammatory bowel disease (IBD), which causes chronic inflammation of the intestinal tract. It can be painful and debilitating and may lead to life-threatening complications. Although there is no medical cure for Crohn’s disease there are therapies that reduce signs and symptoms and even achieve long-term remission.
Cannabinoids help bring remission in Crohn’s disease
Independent clinical trials suggest cannabinoids help induce remission in Crohn’s disease patients as the vast majority of IBD sufferers on cannabinoid medication experienced symptomatic relief. More than 75% found improvement in visceral pain and abdominal cramps.
Approximately 1.4 million people in America have IBDs, which include Crohn’s Disease and ulcerative colitis. Most patients are diagnosed before age 30, and they require lifelong medication. Cannabidiol (CBD) is ideally used in combination treatment regimens as a non-psychotropic treatment for neurological conditions with very few side effects. The prodrugs could provide the same therapeutic benefits with notable improvement in patient compliance, and better oral bioavailability, providing safer and more reliable dosing and a delayed release formulation to deliver long-lasting relief.
A selection of our products
Prodrugs reduce THC delivery
According to researchers, the high concentrations of psychoactive THC reaching the brain currently limit the dose of cannabinoids that can be used to treat pain and inflammation elsewhere in the body.
Recently intellectual property applications for more than 30 cannabinoid prodrugs were filed by Vitality Biopharm. Targeted cannabinoids including THC, CBD, and CBDV. This demonstrates the ability to create a prodrug for every significant cannabinoid available today.
CBD for Crohn’s disease
Today Crohn’s patients may have a better chance of living normal lives than ever before. Research indicates access to affordable CBD (cannabidiol) and cannabis products could lessen the pain and expense associated with Crohn’s disease. If you suffer from Crohn’s disease, you will be encouraged by the mounting evidence for CBD cannabidiol as an effective treatment. It may prevent surgery and can even save lives.
An unanswered question
High CBD varieties of cannabis do not have the high-THC disadvantage. Superficial capillaries in the anus allow for direct absorption of CBD from suppositories into the bloodstream at site. Are prodrugs even necessary in this case?
Disclaimer: Views expressed here do not necessarily reflect those of Endoca and its staff. This article is not intended to provide medical advice, diagnosis, treatment or cure. Endoca CBD products have not been approved by the US Food and Drug Administration (FDA).